JPWO2020243224A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243224A5 JPWO2020243224A5 JP2021570326A JP2021570326A JPWO2020243224A5 JP WO2020243224 A5 JPWO2020243224 A5 JP WO2020243224A5 JP 2021570326 A JP2021570326 A JP 2021570326A JP 2021570326 A JP2021570326 A JP 2021570326A JP WO2020243224 A5 JPWO2020243224 A5 JP WO2020243224A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- heterocyclic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000002837 carbocyclic group Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 16
- 229910052805 deuterium Inorganic materials 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims 7
- 229960004287 clofazimine Drugs 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229960004099 azithromycin Drugs 0.000 claims 6
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 6
- 229960002626 clarithromycin Drugs 0.000 claims 6
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853273P | 2019-05-28 | 2019-05-28 | |
| US62/853,273 | 2019-05-28 | ||
| PCT/US2020/034794 WO2020243224A1 (en) | 2019-05-28 | 2020-05-28 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536043A JP2022536043A (ja) | 2022-08-12 |
| JPWO2020243224A5 true JPWO2020243224A5 (https=) | 2023-05-31 |
| JP2022536043A5 JP2022536043A5 (https=) | 2023-05-31 |
Family
ID=73553908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570326A Pending JP2022536043A (ja) | 2019-05-28 | 2020-05-28 | シトクロムｂｃ１阻害剤とクラリスロマイシン又はアジスロマイシン及びクロファジミンを組み合わせることを特徴とするマイコバクテリア感染症治療用医薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220235047A1 (https=) |
| EP (1) | EP3976031A4 (https=) |
| JP (1) | JP2022536043A (https=) |
| WO (1) | WO2020243224A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI861208B (zh) * | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| TW202237116A (zh) * | 2020-12-02 | 2022-10-01 | 日商塩野義製藥股份有限公司 | 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125171C2 (uk) * | 2015-07-02 | 2022-01-26 | Янссен Саєнсиз Айрленд Юсі | Антибактеріальні сполуки |
| KR20180053386A (ko) * | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| EP3266454A1 (en) * | 2016-07-07 | 2018-01-10 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Acc inhibitors for use in treating mycobacterial diseases |
| KR20190121315A (ko) * | 2017-03-01 | 2019-10-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
-
2020
- 2020-05-28 EP EP20814041.8A patent/EP3976031A4/en active Pending
- 2020-05-28 US US17/614,407 patent/US20220235047A1/en active Pending
- 2020-05-28 WO PCT/US2020/034794 patent/WO2020243224A1/en not_active Ceased
- 2020-05-28 JP JP2021570326A patent/JP2022536043A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6403564B1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2005509642A5 (https=) | ||
| EP1746885A1 (en) | Agonists of a2a adenosine receptors for treatment of diabetic nephropathy | |
| US20020055473A1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| PT707481E (pt) | Analogos de l-2',3'-didesoxinucleosido como agentes anti-hepatite b (hbv) e anti-hiv | |
| WO2000023455A9 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| US5869461A (en) | Reducing toxicity of L-nucleosides with D-nucleosides | |
| JP2005502621A5 (https=) | ||
| WO2007120972A2 (en) | Method to treat sickle cell disease | |
| US6673775B2 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| EP1121369B1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JPWO2021030555A5 (https=) | ||
| JP2009530295A5 (https=) | ||
| JP2013528659A5 (https=) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| US20100069291A1 (en) | Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| AU732120B2 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
| JPH02160769A (ja) | 新規な２′―ハロメチリデン、２′―エテニリデン及び２′―エチニルアデノシン誘導体類 | |
| JPH1036365A5 (https=) | ||
| JPWO2020243224A5 (https=) | ||
| KR940702726A (ko) | 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법 | |
| JP2010533720A (ja) | 不安を処置するための方法 | |
| JP2007500205A5 (https=) | ||
| RU2004109817A (ru) | Производные аминопиррола в качестве противовоспалительных средств |